These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035 [TBL] [Abstract][Full Text] [Related]
6. Metastasis-directed Therapy (SBRT) Guided by PET-CT Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189 [TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712 [TBL] [Abstract][Full Text] [Related]
8. Stereotactic Radiotherapy for Lesions Detected via Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700 [TBL] [Abstract][Full Text] [Related]